Investor in PLTR, IBRX, ONDS and EOSE. Former banker and buy-side analyst at UBS . I care about Alzheimer and alternative medicine.
Lucerne, Switzerland
Joined March 2007
- Tweets2.3K
- Following1K
- Followers2.6K
- Likes31.5K
$IBRX
Danny Cheng has posted his proprietary daily chart on ImmunityBio this morning.
Please take note of the risks his chart shows: tightening red ribon which could mean a drop in share price, and his warning that $9.30 has to be reclaimed soon.
$IBRX
In the weekly chart the share price has managed to reclaim the uptrend channel that has been in force since July. Since July the share price has been inching up on the lowest trend line, week after week, until the end of September / beginning of October, when we had a strong surge up to $10.80, followed by a back testing of the lower trend line.
The two most likely scenarios in my view are a continued slow upward crawl at the bottom of the upward channel, or a new try to break into the next higher upward channel.
A noteworthy point: the share price bounced after briefly dipping below the blue 20 week moving average, as shown in the Bollinger Band.
$IBRX
Please study Danny's daily chart on ImmunityBio, and listen to what he is highlighting:
- Support: $8.44
- Resistance: $8.77 and $9.20 (if $9.20 is not reclaimed, increased risk of a downward trend
- the downward pointing arrow is highlighting that whales are selling!
Thank you Danny, I always value your unbiased view!
If you are not already following @dannycheng2022 and also @cantonmeow, do yourself a favor and follow them.
$IBRX (October 20, 2026-Daily Chart)
The triple volatility holes combined with the last bearish yellow candle have marked a temporary top.
Momentum bar at $8.44 is acting as near-term support, with near-term resistance at $8.77 and additional resistance at $9.20 (the lower edge of the bullish red ribbon). Failure to reclaim $9.20 increases the probability of a downtrend developing.
@DavidDin
$IBRX
And this is something that I have learned from the best: if you want to start a position or add to your existing position, it is better to do so at support than at resistance.
Technically we are under the trendline, so at this moment it is resistance. If the share price surpasses 8.99 $, the trendline turns into support.
@dannycheng2022
@cantonmeow
$IRBX
The daily chart of ImmunityBio clearly shows that the lowest trend line has been serving as support since July.
And today's price action is showing a green candle that wants to go back into the upward channel.
If the share price moves back into this upward channel, the upward trend can continue.
$IBRX
I have posted this chart this morning.
So far, the support line seems to be holding, and maybe we might even see some sort of trend reversal.
$IBRX
I have been thinking about sharing this chart on $IBRX for a long time, but always thought it might be too simple. But maybe it will help some people after the recent pullback.
The lines in this chart show trend channels that have been forming since January.
The interesting thing in my view is that the lowest line has so far been a strong support.
Share price was not able to break resistance and went back all the way to support. The question remains: is this just a healthy backtest, or will the strong support be breached this time?
Even if the lowest support line should be breached, there is still the Ichimoku cloud just below that might serve as an additional support.
$IBRX
I have been thinking about sharing this chart on $IBRX for a long time, but always thought it might be too simple. But maybe it will help some people after the recent pullback.
The lines in this chart show trend channels that have been forming since January.
The interesting thing in my view is that the lowest line has so far been a strong support.
Share price was not able to break resistance and went back all the way to support. The question remains: is this just a healthy backtest, or will the strong support be breached this time?
Even if the lowest support line should be breached, there is still the Ichimoku cloud just below that might serve as an additional support.
This hospital in Florida was able to reduce sepsis deaths by over 50% by using Palantir software.
This is proof that hospitals do care about sepsis.
You can’t be bullish enough on $IBRX
$ IBRX
It’s been a long time since I have posted any charts of mine.
Today we almost dropped below the support in my chart.
$IBRX
I cannot be the only one who has noticed how young and energetic our good doctor @DrPatrick looks.
He has stated that he took Anktiva during the Covid time, and that he never jad the virus, because the BioShield would have cleared the virus immediately.
But Anktiva also gave him longevity in my view.
Check out this article where they seem to have found something that is clearing senescent cells and reversing biological aging. I would not be surprised if Anktiva has the same effect. How about a trial where they are targeting metabolic aging as the indication itself?
And this does not only work in humans, but also in dogs. As the proud father of a a wonderful and lovely dog, I would do anything for my Lucky.
When I started doing intratumoral immunotherapy years ago, I noticed something I wasn't expecting. Some of my patients seemed to be getting younger. Not just responding to cancer treatment, actually looking and functioning younger. That observation is what pulled me into longevity medicine in the first place. The drugs activating the immune system against cancer were also clearing senescent cells and reversing biological aging in the same patients.
Which is why this dog study matters more than people realize. LOY-002 isn't treating a disease. It's targeting metabolic aging as the indication itself. That's a regulatory first, and it only happened because the veterinary side moves faster than the human side does on questions like this.
The same biology drives both processes. Senescent cell accumulation. Immune decline. Chronic inflammation. Mitochondrial dysfunction. Cancer is a disease of the aged cell, not the aged person. Which is why we're now seeing it in 30 year olds. Whatever Loyal learns over the next four years is going to flow upstream into how we think about intervention in humans.
The cancer field and the longevity field have been treated as separate conversations for a long time. They were never separate. This study is one of the first regulatory acknowledgments of that.
$IBRX
It’s been a while since we heard news from Saudi Arabia.
I am looking forward to see how much revenue will come from them in 2026.
And Saudi definitely remains the dark horse when it comes to authorizing new approvals for Anktiva. The one approval the world is waiting for is for Lymphopenia.
$IBRX
I agree that 9$ is an important hurdle for the next move upwards.
Still, it seems there is strong selling pressure around 8.50$
The reason why many or even most nonprofit cancer organizations are not talking about ImmunityBio might be simply because the mainstream media is not talking about $IBRX
I told my doctor in Switzerland about it, urged him to buy shares and explained the story to him. He is a really exceptional generalist, and still he was unaware ot it.
The Streisand effect in full display for $IBRX. What is really sad, where are the large cancer fighting Non-Profits screaming? They aren't because it is bad for donations. Criminal.
In these newspaper articles they talk about the TOXIC CULTURE AT THE FDA UNDER MAKARY.
We are all curious to see if this unprofessional behavior will be addressed by the new head of the FDA.
$IBRX In The Wall Street Journal’s weekend edition, two self explanatory articles on the Editorial page:
